GlassScriptPhysician profile
David Benhayon
NPI 1083824130
$5,455.70
in general payments reported to CMS, 2019-2025
43 companies · $599 in 2025
The $599 reported for 2025 was more than what 78% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $393 · 2021: $766 · 2022: $1,028 · 2023: $1,628 · 2024: $870 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,097.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,180.84 | 2020-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $495.07 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $381.31 | 2020-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $291.25 | 2020-2025 | Vyepti, Rexulti |
| Abbvie INC. | $278.93 | 2021-2025 | Vraylar, Duopa |
| Novartis Pharmaceuticals Corporation | $251.87 | 2020-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $244.38 | 2020-2025 | Caplyta |
| Neurelis, INC. | $197.18 | 2020-2024 | Valtoco |
| Vanda Pharmaceuticals INC. | $162.48 | 2021-2025 | Fanapt |
| Ucb, INC. | $129.32 | 2019-2024 | Rystiggo |
| Axsome Therapeutics, INC. | $124.91 | 2023-2024 | Auvelity, Sunosi |
| Tanabe Pharma America, INC. | $122.47 | 2020-2023 | |
| Alkermes, INC. | $121.49 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $120.90 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $115.27 | 2022-2024 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $114.88 | 2019-2023 | Aimovig |
| Sk Life Science, INC. | $103.06 | 2021-2024 | |
| Grifols USA, LLC | $97.12 | 2021-2024 | Gamunex-C |
| Eisai INC. | $78.87 | 2021 | |
| Corium, LLC | $73.68 | 2023 | Azstarys |
| Kyowa Kirin, INC. | $60.45 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $59.14 | 2022-2025 | Invega Sustenna |
| Abbott Laboratories | $57.75 | 2019 | |
| Greenwich Biosciences, INC. | $57.44 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $55.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.22 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $47.20 | 2023-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $42.13 | 2025 | Jornay Pm |
| Banner Life Sciences, LLC | $37.44 | 2022 | |
| Csl Behring | $34.39 | 2024 | Hizentra |
| Alexion Pharmaceuticals, INC. | $34.10 | 2022-2023 | Ultomiris |
| Lilly USA, LLC | $33.84 | 2022-2023 | Amyvid |
| Merck Sharp & Dohme LLC | $29.53 | 2021-2023 | Belsomra |
| Harmony Biosciences LLC | $22.93 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.25 | 2025 | Cobenfy |
| Argenx US, INC. | $17.63 | 2023 | Vyvgart |
| Vertical Pharmaceuticals, LLC | $16.77 | 2019 | |
| Emd Serono, INC. | $16.55 | 2023 | Mavenclad |
| Genentech USA, INC. | $16.42 | 2023 | Enspryng |
| Catalyst Pharmaceuticals, INC. | $15.88 | 2019 | |
| Impel Pharmaceuticals INC. | $14.98 | 2023 | Trudhesa |
| Allergan, INC. | $14.88 | 2019 | |
| Currax Pharmaceuticals LLC | $13.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Benhayon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.